US20100104599A1 - Compositions and Methods For Enhancing Immune System of Felines - Google Patents

Compositions and Methods For Enhancing Immune System of Felines Download PDF

Info

Publication number
US20100104599A1
US20100104599A1 US12/528,153 US52815308A US2010104599A1 US 20100104599 A1 US20100104599 A1 US 20100104599A1 US 52815308 A US52815308 A US 52815308A US 2010104599 A1 US2010104599 A1 US 2010104599A1
Authority
US
United States
Prior art keywords
composition
feline
ppm
compositions
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/528,153
Other languages
English (en)
Inventor
Ryan Michael Yamka
Kim Gene Friesen
Steven Curtis Zicker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hills Pet Nutrition Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US12/528,153 priority Critical patent/US20100104599A1/en
Assigned to HILL'S PET NUTRITION, INC. reassignment HILL'S PET NUTRITION, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ZICKER, STEVEN CURTIS, FRIESEN, KIM GENE, YAMKA, RYAN MICHAEL
Publication of US20100104599A1 publication Critical patent/US20100104599A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/105—Aliphatic or alicyclic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/174—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/20—Inorganic substances, e.g. oligoelements
    • A23K20/30—Oligoelements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to compositions and methods for enhancing the immune system of mammals.
  • pet foods e.g., cat food
  • compositions specially formulated to address many different nutritional needs include, for example, formulations designed for different breed types, sizes and body conditions. They also include formulations designed to address the nutritional needs of animals in the different stages of their life cycle. Despite the availability of such pet food formulations, however, there is a need to develop formulations and methods to address other aspects of an animal's health.
  • Pets are constantly exposed to pathogens. Failure to respond to those pathogens may result in chronic illness and death. Response to pathogens may be inhibited by an animal's diet, preventing an adequate immune response. Thus compositions and methods are needed to enhance an animal's immune response against challenges by pathogens.
  • Vaccines are not 100% effective, as some cats vaccinated against a particular disease will not be immunized against that disease.
  • compositions and methods to increase the efficacy of vaccines, and to enhance a feline's immune response when challenged with an antigen.
  • the present invention relates to compositions that are useful to enhance the immune system or immune response of an animal when challenged with an antigen.
  • the present invention includes Composition 1.0, a pet food composition useful to enhance immune function in an animal comprising:
  • the present invention also includes the following compositions:
  • compositions of the present invention may be a wet, dry, or semi-dry food.
  • the present invention includes Method 2.0, a method to enhance the neurologic development of a feline comprising administering to the feline any one of compositions 1.0-1.18.
  • the present invention also includes the following methods:
  • the present invention relates to any animal, preferably a mammal, more preferably a companion animal.
  • the term “companion animal” refers to any animal that lives in close association with humans and includes, but is not limited to, canines and felines of any breed. It is contemplated herein, however, that any animal whose diet may be controlled by humans may benefit from feeding the formulations disclosed herein. These animals may include, for example, domesticated farm animals (e.g., cattle, horses, swine, etc.) as well as undomesticated animals held in captivity, e.g., in zoological parks and the like. Preferably, the animal is a feline, either a kitten, or adult cat.
  • an amount effective to” or “an effective amount” to achieve a particular result refers to that amount of a compound, material or composition as described herein that may be effective to achieve a particularly desired biological result.
  • results include, for example, enhancement of neurologic development, bone and joint health, immune function and/or promotion of a healthy body composition of an animal, either while developing in utero and/or during its growth stage after birth, e.g., up to 6 months, 9 months, 12 months, or 15 months after birth.
  • Such effective activity may be achieved, for example, by administration of compositions of the present invention to the dam of said animal while the animal is in utero or nursing, as well as by direct administration to the animal during its growth stage.
  • the “enhancement” of a particular biological process or body condition in a growing animal refers to an improvement in the biological process or body condition of a growing animal compared to a control animal. Improvement in such a process or condition may be determined by one of skill in the art. Immune function may be determined in an animal by assaying antibody titers in response to vaccination and comparing to control animals, where an increase in antibody titer compared to controls is indicative of an enhancement in adaptive immune function.
  • “enhancement of the development of a growing animal” or “enhanced growth” and like terms refer to an overall improvement in one or more biological processes and/or the body condition of a growing animal, including but not limited to, biological processes central to the growth and development of an organism, including, but not limited to, the biological processes described herein, e.g., bone and joint health, neurologic and immune system development and body weight gain (e.g., increase in lean muscle mass instead of adipose tissue).
  • the “growth” life stage of an animal refers to the period from birth or weaning (approx 8 weeks of age) to about 1 year of age.
  • feline refers to an immature feline, typically between the ages of birth and 12 months.
  • “Essential amino acids” as used herein refers to those amino acids that cannot be synthesized de novo by an organism and thus must be supplied in the diet. It is understood by one of skill in the art that the essential amino acids vary from species to species, depending upon the organism's metabolism. For example, it is generally understood that the essential amino acids for dogs and cats (and humans), are phenylalanine, leucine, methionine, lysine, isoleucine, valine, threonine, tryptophan, histidine and arginine. In addition, taurine, while technically not an amino acid but a derivative of cysteine, is an essential for cats. A balanced diet can provide all the essential amino acids, however, there are certain essential amino acids that are more critical, as a diet deficient in one of them will limit the usefulness of the others, even if the other essential amino acids are present in sufficient quantities.
  • a “limiting amino acid” refers to an amino acid which if present in insufficient quantities in a diet, results in the limitation in usefulness of other essential amino acids, even if the other essential amino acids are present in otherwise large enough quantities.
  • Lysine is the limiting essential amino acid in the compositions disclosed herein.
  • the remaining essential amino acids are quantitatively formulated or “balanced” in relationship to the amount of lysine determined critical to effect the desired biological result.
  • balanced amino acids refers to the relationship of the essential amino acid lysine to energy to assure optimal animal growth and development.
  • “Essential nutrients” as used herein refers to nutrients required for normal body functioning that cannot be synthesized by the body. Categories of essential nutrient include vitamin dietary minerals, fatty acid, and amino acid. It is understood by one of skill in the art that the nutrients deemed essential varies from species to species, depending upon the organism's metabolism. For example, essential nutrients for dogs and cats include Vitamins A, D, E, K, B1, B6 B12, riboflavin, niacin, pantothenic acid, folic acid, calcium, phosphorous, magnesium, sodium, potassium, chlorine, iron, copper, zinc, manganese, selenium and iodine. Choline, generally regarded as a B complex vitamin, may be included among the semi-essential nutrients.
  • Carnitine also known as L-carnitine, (levocarnitine) is a quaternary ammonium compound synthesized from the amino acids lysine and methionine and is responsible for the transport of fatty acids from the cytosol into the mitochondria.
  • immune response is generally the mechanisms within an organism that protects against disease, e.g., by identifying and killing pathogens and tumor cells.
  • Immune responses may be classified into various response types, e.g., humoral or cell-mediated response, and innate and adaptive response.
  • immune responses may be humoral innate responses, cell-mediated innate response, cell-mediated adaptive response, and cell-mediated adaptive response, and combinations thereof. It is well known that these responses may occur concurrently when an animal is challenged, e.g., with a pathogen.
  • the complement cascade of the innate humoral immune response may recruit T and B cells, which form the basis of cell-mediated adaptive immunity, and complement may be recruited by the adaptive immune system.
  • the present invention is based on the surprising discovery that the diet of an animal may enhance the animal's immune response to antigens, e.g., pathogens or vaccines. Addition of certain ingredients to pet food compositions and administration of these compositions to animals can enhance the immune system of a growing animal. Additionally, the addition of certain ingredients to pet food compositions and administration of these compositions to dams during pregnancy can enhance the immune system of the offspring thereof.
  • antigens e.g., pathogens or vaccines.
  • the present invention contemplates that the immune response of a feline may be enhanced or augmented against any number of antigens, including pathogens and vaccines.
  • Felines may be vaccinated against any number of diseases or conditions, including feline panleukopenia, feline herpesvirus-1, feline calicivirus, feline leukemia virus, rabies, chlamydiosis, feline infectious peritonitis, bordetella bronchiseptica infection, dermatophytosis, giardiasis, etc.
  • the present invention contemplates an improved method of establishing enhanced adaptive humoral immunity, e.g., against a pathogen comprising the methods of the present invention, and immunizing an animal against a pathogen with a vaccine for the pathogen.
  • Enhanced immune function in an animal may be characterized as an immune response which demonstrates greater antibody or cell-mediated response upon antigen challenge than control animals.
  • compositions of the present invention comprise nutritionally complete and balanced animal feed compositions.
  • Such compositions include, among other nutrients and ingredients, recommended healthful amounts of protein, carbohydrate and fat.
  • “Nutritionally complete and balanced animal feed compositions”, as well as nutrients and ingredients suitable for animal feed compositions, and recommended amounts thereof, are familiar to one of skill in the art (see, for example, National Research Council, 2006 Nutritional Requirements for Dogs and Cats, National Academy Press, Washington D.C. or the Official Publication of the Association of American Feed Control Officials, Inc. Nutrient Requirements for Dogs and Cats 2006).
  • compositions disclosed herein may also comprise antioxidants, additives, stabilizers, thickeners, flavorants, palatability enhancers and colorants in amounts and combinations familiar to one of skill in the art.
  • Antioxidants refers to a substance that is capable of reacting with or decreasing the production of free radicals and neutralizing them.
  • Examples include, but are not limited to, beta-carotene, selenium, coenzyme Q10 (ubiquinone), lutein, tocotrienols, soy isoflavones, S-adenosylmethionine, glutathione, taurine, N-acetylcysteine, vitamin E, vitamin D, vitamin C, flavanoids, anthocyanindins, and lipoic acid.
  • compositions of the present invention may be, for example, a wet, semi-dry or dry animal food composition.
  • “Wet” food refers to food which is sold in cans or foil bags and has a moisture content of about 70 to about a 90%.
  • “Dry” food refers to compositions with about 5 to about 15% moisture content and is often manufactured in the form of small bits or kibbles.
  • Semi-dry compositions refer to compositions having about 15% to about 70% moisture.
  • compositions of intermediate moisture consistency and those that may comprise components of various consistency as well as components that may include more than one consistency, for example, soft, chewy meat-like particles as well as kibble having an outer cereal component and an inner cream component as described in, e.g., U.S. Pat. No. 6,517,877.
  • ranges are used as shorthand for describing each and every value that is within the range. Any value within the range can be selected as the terminus of the range. It is understood that when formulations are described, they may be described in terms of their ingredients, as is common in the art, notwithstanding that these ingredients may react with one another in the actual formulation as it is made, stored and used, and such products are intended to be covered by the formulations described.
  • Formulations to enhance the development of growing animal are disclosed hereinbelow. These compositions are developed taking into account the “ideal protein concept” (Baker and Czarnecki-Maulden, 1991 Annu. Rev. Nutr. 11:239-63).
  • Foods are developed for the “growth” life stage. These foods include formulations for canine growth and feline growth. The minimum nutrient recommendations for these foods, as well as the targeted values for a prototype food, are listed below in Table 1.
  • the 48 kittens are vaccinated against rabies, and anti-rabies antibody titers were determined prior to vaccination, and at 1, 2, 4, 8 and 16 weeks following vaccination.
  • Results are presented in Table 3. Kittens from queens fed Formula X and continued to feed on Formula X have significantly improved immune response, as measured by increased antibody titer to the rabies vaccination. The antibody titer in kittens is significantly increased when Formula X is fed to queens during gestation and lactation, and to the kittens after weaning during growth.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US12/528,153 2007-02-22 2008-02-22 Compositions and Methods For Enhancing Immune System of Felines Abandoned US20100104599A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/528,153 US20100104599A1 (en) 2007-02-22 2008-02-22 Compositions and Methods For Enhancing Immune System of Felines

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89117107P 2007-02-22 2007-02-22
US12/528,153 US20100104599A1 (en) 2007-02-22 2008-02-22 Compositions and Methods For Enhancing Immune System of Felines
PCT/US2008/054789 WO2008103950A1 (en) 2007-02-22 2008-02-22 Compositions and methods for enhancing immune system of felines

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/054789 A-371-Of-International WO2008103950A1 (en) 2007-02-22 2008-02-22 Compositions and methods for enhancing immune system of felines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/876,451 Division US9848622B2 (en) 2007-02-22 2010-09-07 Compositions and methods for enhancing immune system of felines

Publications (1)

Publication Number Publication Date
US20100104599A1 true US20100104599A1 (en) 2010-04-29

Family

ID=39563552

Family Applications (6)

Application Number Title Priority Date Filing Date
US12/528,362 Abandoned US20100137404A1 (en) 2007-02-22 2008-02-22 Compositions and Methods for Altering Gene Expression
US12/528,137 Abandoned US20110059202A1 (en) 2007-02-22 2008-02-22 Compositions and Methods For Enhancing The Development of Growing Animals
US12/528,164 Active 2030-05-31 US9888709B2 (en) 2007-02-22 2008-02-22 Compositions and methods for enhancing neurological development
US12/528,153 Abandoned US20100104599A1 (en) 2007-02-22 2008-02-22 Compositions and Methods For Enhancing Immune System of Felines
US12/528,158 Abandoned US20100143497A1 (en) 2007-02-22 2008-02-22 Compositions and Methods For Promoting Bone Development
US12/876,451 Active US9848622B2 (en) 2007-02-22 2010-09-07 Compositions and methods for enhancing immune system of felines

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US12/528,362 Abandoned US20100137404A1 (en) 2007-02-22 2008-02-22 Compositions and Methods for Altering Gene Expression
US12/528,137 Abandoned US20110059202A1 (en) 2007-02-22 2008-02-22 Compositions and Methods For Enhancing The Development of Growing Animals
US12/528,164 Active 2030-05-31 US9888709B2 (en) 2007-02-22 2008-02-22 Compositions and methods for enhancing neurological development

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/528,158 Abandoned US20100143497A1 (en) 2007-02-22 2008-02-22 Compositions and Methods For Promoting Bone Development
US12/876,451 Active US9848622B2 (en) 2007-02-22 2010-09-07 Compositions and methods for enhancing immune system of felines

Country Status (12)

Country Link
US (6) US20100137404A1 (zh)
EP (5) EP2129237B1 (zh)
JP (5) JP5285625B2 (zh)
CN (6) CN101686712B (zh)
AU (5) AU2008218195C1 (zh)
BR (5) BRPI0807373A2 (zh)
CA (5) CA2678938C (zh)
DK (1) DK2129237T3 (zh)
ES (1) ES2546284T3 (zh)
RU (5) RU2435435C2 (zh)
WO (5) WO2008103956A1 (zh)
ZA (5) ZA200906390B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140044828A1 (en) * 2011-04-13 2014-02-13 Ajinomoto Co., Inc. Nutritional composition

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1937721T3 (pl) * 2005-08-25 2010-12-31 Lilly Co Eli Przeciwciała anty-IL23
WO2008103956A1 (en) * 2007-02-22 2008-08-28 Hill's Pet Nutrition, Inc. Compositions and methods for promoting bone development
CN102316865B (zh) * 2008-12-12 2017-04-19 科耐特有限公司 用于改善正常的认知功能的l‑赖氨酸
DK2493491T3 (da) 2009-12-29 2014-06-30 Hills Pet Nutrition Inc Sammensætninger, indeholdende ingefær til lindringen eller forebyggelsen af inflammatoriske tilstande hos katte og hunde
RU2012153677A (ru) * 2010-05-12 2014-06-20 Хилл'С Пет Ньютришн, Инк. Способы диагностики, контроля и профилактики воспаления и облегчения воспалительных состояний у кошачьих
US20130273196A1 (en) * 2010-12-20 2013-10-17 Hill's Pet Nutrition, Inc Pet Food Compositions for Inducing a Satiety Response
US8828426B2 (en) 2011-06-07 2014-09-09 Zx Pharma, Llc Multiparticulate L-carnitine compositions and related methods
WO2013095935A1 (en) 2011-12-19 2013-06-27 Hill's Pet Nutrition, Inc. Compositions and methods for diagnosing and treating hyperthyroidism in companion animals
CN103315187B (zh) * 2013-07-17 2014-11-05 江苏桂龙生物技术有限公司 一种预防宠物骨骼性疾病的饲料
CN104026401B (zh) * 2014-06-10 2016-04-27 务川县绿之源农业技术推广中心 一种小型幼犬粮
EP3213640B1 (en) * 2014-10-30 2021-07-21 Fuji Oil Holdings Inc. Long-chain polyunsaturated fatty-acid-containing fat and food containing same
GB201522300D0 (en) * 2015-12-17 2016-02-03 Mars Inc Puppy growth food product
AU2017376984B2 (en) 2016-12-15 2021-12-23 Société des Produits Nestlé S.A. Compositions and methods for small canines
EP3554256B1 (en) 2016-12-15 2023-07-19 Société des Produits Nestlé S.A. Compositions and methods that modulate vitamin d and bone mineral content in a companion animal
US11813238B2 (en) * 2017-05-29 2023-11-14 Societe Des Produits Nestle S.A. Medium chain fatty acids for use in the prevention or treatment of cardiac enlargement and/or valvular heart disease
US20190240180A1 (en) * 2018-02-08 2019-08-08 Nestec Sa Mct-based nutrition blend for providing health benefits in companion animals
CN108244374A (zh) * 2018-02-27 2018-07-06 佛山市雷米高动物营养保健科技有限公司 猫用营养粉剂及其制备方法
KR20210120091A (ko) * 2019-02-01 2021-10-06 마아즈, 인코오포레이티드 고양잇과 동물용 사료 조성물
CN110537630A (zh) * 2019-09-09 2019-12-06 天津农学院 1，2二硫戊环-3-戊酸的应用、幼犬鲜粮和延长幼犬鲜粮贮藏期的方法
AU2020410289A1 (en) * 2019-12-19 2022-05-26 Societe Des Produits Nestle Sa Compositions and methods for providing a health benefit to a growing animal
EP4202564A1 (fr) 2021-12-22 2023-06-28 The Swatch Group Research and Development Ltd Mouvement mecanique horloger comprenant un balancier pivote magnetiquement
WO2023150389A1 (en) * 2022-02-07 2023-08-10 Cornell University Compositions and methods for increasing dha availability

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130651A (en) * 1978-03-31 1978-12-19 American Cyanamid Company Butamisole injectable formulations having improved margin of safety in dogs
US5690988A (en) * 1996-02-02 1997-11-25 Colgate Palmolive Company Pet food composition of improved palatability and a method of enhancing the palatability of a food composition
US5851573A (en) * 1997-04-29 1998-12-22 The Iams Company Pet food composition for large breed puppies and method for promoting proper skeletal growth
WO2006074089A2 (en) * 2004-12-30 2006-07-13 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
US20100093859A1 (en) * 2007-02-22 2010-04-15 Hill's Pet Nutrition, Inc. Compositions and Methods For Enhancing Neurological Development

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267195A (en) * 1976-09-10 1981-05-12 University Of Texas Dog food flavors
JPH0625057B2 (ja) 1987-12-14 1994-04-06 日本油脂株式会社 骨形成促進剤
JPH04166039A (ja) * 1990-10-26 1992-06-11 Hirotoshi Yokura ペットフード
US6156355A (en) * 1998-11-02 2000-12-05 Star-Kist Foods, Inc. Breed-specific canine food formulations
GB2367489B (en) * 2000-07-31 2005-02-09 Mars Inc Use of antioxidants
NZ527924A (en) 1999-01-29 2005-01-28 Mars Uk Ltd Antioxidant compositions and methods for companion animals
US6071544A (en) * 1999-04-01 2000-06-06 The Iams Company Dietary compositions and method for promoting healthy weight loss cats
IL146438A0 (en) * 1999-05-27 2002-07-25 Iams Company Process and product for enhancing immune response in companion animal using a combination of antioxidants
EG22407A (en) * 2000-02-17 2003-01-29 Iams Company Method for improving bone modeling and chondrocyte functioning in growing canines
GB2367487A (en) 2000-10-04 2002-04-10 John Kennedy Mcmillan Tooth cleaner
ATE402615T1 (de) 2000-12-29 2008-08-15 Martin Francis Gannon Tiernahrungsmittelzusammensetzung
US6582752B2 (en) * 2001-11-02 2003-06-24 Nestec, Ltd Methods and compositions for a gender specific diet for puppies
WO2004006688A1 (en) 2002-07-12 2004-01-22 The Iams Company Synergistic effect of diet and human interaction on the behavior of dogs
WO2004008196A1 (ja) * 2002-07-13 2004-01-22 Autocloning Technology Ltd. 偏光解析装置
EP1524912A1 (en) 2002-07-26 2005-04-27 DSM IP Assets B.V. Compositions comprising lactoferrin
US20070082008A1 (en) 2003-03-07 2007-04-12 Advanced Bionutrition Corporation Feed formulation for terrestrial and aquatic animals
WO2004095940A1 (en) 2003-04-25 2004-11-11 The University Of Newcastle Biomass containing animal feed
WO2005006877A1 (en) * 2003-07-03 2005-01-27 Hill's Pet Nutrition, Inc. Compositions and methods for decreasing age-related deterioration in metal activities in companion animals
RU2358440C2 (ru) 2003-07-07 2009-06-20 Хилл`С Пет Ньютришн, Инк. Композиция для улучшенного окислительного статуса домашних животных
US8128956B2 (en) * 2003-09-12 2012-03-06 Mars, Inc. Food product for hairball treatment
US8921422B2 (en) * 2003-10-01 2014-12-30 The Iams Company Methods and kits for enhancing ability to learn in a puppy or kitten
US20050266051A1 (en) 2004-05-27 2005-12-01 The Procter & Gamble Company Pet food compositions and methods
AU2005280008B2 (en) * 2004-08-30 2011-06-16 Hill's Pet Nutrition, Inc. Genome-based diet design
CN1631207A (zh) 2004-12-03 2005-06-29 王志文 能改善猫狗皮毛质量的不饱和脂肪酸饲料添加剂及饲料
CA2592827C (en) 2004-12-30 2013-08-13 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a growing animal
EP1928552A2 (en) * 2005-09-30 2008-06-11 Nestec S.A. Methods and compositions for improving cognitive function
WO2007082231A1 (en) * 2006-01-10 2007-07-19 Hill's Pet Nutrition, Inc. Compositions and method for promoting fat loss
JP2009545308A (ja) * 2006-08-09 2009-12-24 ザ アイムス カンパニー 骨の健康及び筋肉の健康を改善する方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130651A (en) * 1978-03-31 1978-12-19 American Cyanamid Company Butamisole injectable formulations having improved margin of safety in dogs
US5690988A (en) * 1996-02-02 1997-11-25 Colgate Palmolive Company Pet food composition of improved palatability and a method of enhancing the palatability of a food composition
US5851573A (en) * 1997-04-29 1998-12-22 The Iams Company Pet food composition for large breed puppies and method for promoting proper skeletal growth
WO2006074089A2 (en) * 2004-12-30 2006-07-13 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
US20100093859A1 (en) * 2007-02-22 2010-04-15 Hill's Pet Nutrition, Inc. Compositions and Methods For Enhancing Neurological Development
US20100137404A1 (en) * 2007-02-22 2010-06-03 Hill's Pet Nutrition, Inc. Compositions and Methods for Altering Gene Expression
US20100143497A1 (en) * 2007-02-22 2010-06-10 Hill's Pet Nutrition, Inc. Compositions and Methods For Promoting Bone Development

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140044828A1 (en) * 2011-04-13 2014-02-13 Ajinomoto Co., Inc. Nutritional composition
US10136669B2 (en) 2011-04-13 2018-11-27 Ajinomoto Co., Inc. Method for decreasing visceral fat or increasing energy consumption

Also Published As

Publication number Publication date
CN101686712A (zh) 2010-03-31
CA2679682C (en) 2012-09-11
EP2129237A1 (en) 2009-12-09
AU2008218195A1 (en) 2008-08-28
RU2009135263A (ru) 2011-03-27
CA2679065C (en) 2014-07-08
RU2412611C1 (ru) 2011-02-27
JP2010518867A (ja) 2010-06-03
ZA200908481B (en) 2014-05-28
CA2679008A1 (en) 2008-08-28
AU2008218187A1 (en) 2008-08-28
BRPI0807790A2 (pt) 2014-06-24
RU2009135261A (ru) 2011-03-27
EP2124611B1 (en) 2016-01-13
AU2008218195C1 (en) 2012-05-24
AU2008218176B2 (en) 2011-09-29
CN101686711A (zh) 2010-03-31
US20110059138A1 (en) 2011-03-10
CA2679682A1 (en) 2008-08-28
CN101686712B (zh) 2015-07-22
RU2436410C2 (ru) 2011-12-20
EP2124612B1 (en) 2015-10-21
JP5286286B2 (ja) 2013-09-11
JP5474570B2 (ja) 2014-04-16
RU2435435C2 (ru) 2011-12-10
CA2678938A1 (en) 2008-08-28
CA2678938C (en) 2012-09-18
US20100093859A1 (en) 2010-04-15
EP2124610A1 (en) 2009-12-02
ZA200906389B (en) 2014-03-26
BRPI0807790B1 (pt) 2017-08-01
AU2008231241A1 (en) 2008-10-02
US20100143497A1 (en) 2010-06-10
RU2441394C2 (ru) 2012-02-10
WO2008103950A1 (en) 2008-08-28
JP5474571B2 (ja) 2014-04-16
JP2010518866A (ja) 2010-06-03
BRPI0807691A2 (pt) 2017-05-02
AU2008218193B2 (en) 2011-09-29
WO2008103956A1 (en) 2008-08-28
BRPI0807372A2 (pt) 2014-05-06
WO2008118586A1 (en) 2008-10-02
ZA200906390B (en) 2014-08-27
AU2008218193A1 (en) 2008-08-28
ZA200906387B (en) 2014-03-26
US9888709B2 (en) 2018-02-13
WO2008103939A1 (en) 2008-08-28
RU2009135231A (ru) 2011-03-27
US20110059202A1 (en) 2011-03-10
CN101662949B (zh) 2013-09-04
EP2129237B1 (en) 2015-06-17
JP5286287B2 (ja) 2013-09-11
ZA200906388B (en) 2014-03-26
RU2427278C2 (ru) 2011-08-27
EP2124612A1 (en) 2009-12-02
JP5285625B2 (ja) 2013-09-11
ES2546284T3 (es) 2015-09-22
BRPI0807373A2 (pt) 2014-05-06
CN101662949A (zh) 2010-03-03
EP2112889A1 (en) 2009-11-04
BRPI0807789A2 (pt) 2014-06-24
RU2009135260A (ru) 2011-03-27
CA2679065A1 (en) 2008-10-02
US20100137404A1 (en) 2010-06-03
AU2008218187B2 (en) 2011-07-07
CA2679008C (en) 2014-08-12
CN101662950A (zh) 2010-03-03
WO2008103958A1 (en) 2008-08-28
CN101662951A (zh) 2010-03-03
JP2010519315A (ja) 2010-06-03
CA2679215C (en) 2015-11-24
US9848622B2 (en) 2017-12-26
CA2679215A1 (en) 2008-08-28
EP2124611A1 (en) 2009-12-02
EP2112889B1 (en) 2015-11-04
JP2010519317A (ja) 2010-06-03
AU2008218195B2 (en) 2011-11-03
JP2010518865A (ja) 2010-06-03
AU2008218176A1 (en) 2008-08-28
AU2008231241B2 (en) 2011-11-10
CN104472871A (zh) 2015-04-01
AU2008218187C1 (en) 2012-02-16
DK2129237T3 (en) 2015-09-14

Similar Documents

Publication Publication Date Title
US9848622B2 (en) Compositions and methods for enhancing immune system of felines
WO2023014651A1 (en) Products and methods for inhibiting respiratory conditions
Mendonça et al. Dietary supplementation of guanidinoacetic acid for sows and their progenies: performance, blood parameters and economic viability at nursery phase
Agbede et al. Influence of microbial phytase on amino acid digestibility of caecectomised laying hens fed marginally low methionine-based diet

Legal Events

Date Code Title Description
AS Assignment

Owner name: HILL'S PET NUTRITION, INC.,KANSAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YAMKA, RYAN MICHAEL;FRIESEN, KIM GENE;ZICKER, STEVEN CURTIS;SIGNING DATES FROM 20090616 TO 20090623;REEL/FRAME:023128/0413

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION